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rized from 1 to 3 in “no”, “quite” and “a lot of expectations”.
The ANOVA test was used to evaluate the impact of the expec-
tations on the measured outcomes. RESULTS: There were 884
patients (360 hips and 524 knees) who replied the two times. In
all the physic-functional expectations items patients showed sta-
tistically signiﬁcant improvements in all HRQOL dimensions
except in the Mental Component Summary (MCS) of the SF-12,
observing an ascending gradient, so the higher the prior-surgery
expectations are, the greater the improvement is, at 12 months
post-surgery. Regarding the two questions about social expecta-
tions, in both of them the results were equal to the physic-
functional expectations in all dimensions. The question about
psychological expectations keeps on showing this signiﬁcant
improvement in all the dimensions with the same ascending
gradient CONCLUSIONS: Patient expectations prior-surgery
were important predictors of improvement outcomes in health
related quality of life at 12 months after THR and TKR.
PMS49
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OBJECTIVES: In a study aimed at measuring the effectiveness of
Adalimumab in HRQL of moderate to severe RA patients as
prescribed by rheumatologists in normal clinical setting in Greece
we examined the HRQL levels and the correlation among HRQL
measures in RA patients. METHODS: An open label, 52-week
follow-up study of 120 patients is being conducted in ten hospi-
tals. In total, 36 RA patients are so far enrolled and 21 CRFs
have been collected. Two generic instruments—the EQ-5D Ques-
tionnaire and the Medical Outcome Study (MOS) Short-Form 36
(SF-36)- and one disease-speciﬁc–the Health Assessment Ques-
tionnaire (HAQ)—were implemented. Correlation analysis was
used to identify the relationship among HRQL measures, and
reliability analysis to test internal consistency. RESULTS: RA
patients’ mean age was 58.5 years (Std.D. 10.8), while 81% were
women. The mean values of the SF-36 scales were: VT 35.2
(Std.D. 33.3), SF 48.2 (Std.D. 38.8), RE 34.9 (Std.D. 47.6), MH
48.7 (Std.D. 21.6), PF 34.5 (Std.D. 22.6), RP 11.9 (Std.D. 28),
BP 33.5 (Std.D. 18.6), GH 38.5 (Std.D. 19.7). 81% of RA
patients had moderate mobility problems and 61.9% with self-
care. Moderate problems in doing usual activities had 81%,
while 42.9% complained about pain/discomfort. 14.3% of RA
patients were extremely anxious/depressed. The mean VAS value
was 28.6 (Std.D. 27.5), while mean HAQ score 1.2 (Std.D. 1.3).
A statistically signiﬁcant correlation was found between HAQ
and all the SF-36 scales. Correlation coefﬁcients ranged from
-0.471 (GH) to -0.786 (PF) at level 0.01. HAQ was strongly
correlated with the mobility (r = 0.531), self-care (r = 0,546),
and usual activity (r = 0,513) of the EQ-5D at level 0.05. Cron-
bach’ alpha coefﬁcients for HAQ, SF-36 and EQ-5D were 0.856,
0.879 and 0.552 respectively. CONCLUSIONS: RA patients
recorded signiﬁcantly low levels of HRQL. The study reveals a
statistically signiﬁcant correlation among HAQ, SF-36 and
EQ-5D.
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OBJECTIVES: To describe the clinical fracture outcomes, health
related QoL and back pain (BP) in postmenopausal women with
osteoporosis treated with teriparatide (Forsteo®) in France.
METHODS: European, prospective, observational study of 36
month duration (18 months: active treatment phase and 18
months: post-treatment follow up) in postmenopausal patients
with osteoporosis that received a prescription of teriparatide.
Clinical fragility fractures, QoL measured by EQ-5D and BP by
a Visual Analogue Scale (VAS) and a questionnaire were col-
lected. RESULTS: Among 309 patients enrolled in France, 223
(72.2%) patients completed the 18 month visit. Follow-up data
were available for 292 (94.5%) patients. At baseline, mean (SD)
age was 74.5 (7.4) years, 96.8% of patients had 2 or more
prevalent fractures occurred after age 40, the mean number of
fractures (SD) was 4.2 (1.7) and median number was 4.0 (inter-
quartile range 3.0–5.0). During the study, 43 women (14.7%)
sustained a total of 48 incident fractures (50.0% clinical verte-
bral, 50.0% non-vertebral). Between baseline and 18 months
visit, EQ-5D Health State Values improved in 63.2% of patients
and median (Q1;Q3) values increased from 0.52 (0.03;0.69) to
0.69 (0.52;0.76). Back pain improved between baseline and 18
months visit: Percentage of patients suffering from back pain
everyday or almost everyday decreased from 76.6% to 31.4%,
moderate or severe back pain from 93.1% to 66.5%, severe
activities limitations from 46.9% to 12.6%. Mean back pain
intensity (VAS [SD]) decreased from 56.2 (24.9) mm to 34.1
(22.5) mm and was improved in 70.3% of patients who had a
baseline intensity over 67 mm. CONCLUSIONS: French patients
with osteoporosis were treated with teriparatide. These patients
had severe osteoporosis associated with back pain which
impacted on daily activities Improved quality of life and back
pain were observed during teriparatide treatment and 14.7% of
patients had a new fracture.
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OBJECTIVES: To maintain good quality of life (QOL) is an
important goal in the management of patients with rheumatoid
arthritis (RA). Since QOL of RA patients is inﬂuenced by many
factors, we quantitatively measured QOL of RA patients based
on Japanese version of EuroQoL (EQ-5D), and we analyzed the
major determinants of EQ-5D in RA patients using a large obser-
vational cohort of RA patients in Japan. METHODS: IORRA
(Institute Of Rheumatology Rheumatoid Arthritis) is an obser-
vational cohort of RA patients established in the Institute of
Rheumatology Tokyo Women’s Medical University since 2000.
Essentially all RA patients who consulted there were registered,
and clinical parameters including the disease activity, use of drugs
and the occurrence of adverse events in daily clinical settings
were assessed biannually based on patient’s report, physician’s
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examination and laboratory data. In this cohort, we evaluated
QOL of RA patients using EQ-5D, and then analyzed the factors
that inﬂuenced on EQ-5D by the analysis of variance. The factors
analyzed here were gender, age, disease duration, disease activity,
disability, and comorbidity. RESULTS: In September 2007, a
total 5,023 RA patients (female 84.2%, average 58.0 years-old,
average disease duration 11.3 years, rheumatoid factor positive
74.8%, patients taking steroid, methotrexate and biologics were
51.0%, 63.6%, and 4.3%, respectively) answered the question-
naire of EQ-5D. The factors aand the percentage of their contri-
butions on EQ-5D were as follows; i) disability assessed by
JHAQ (Japanese Health Assessment Questionnaire): 57.6%,
pain VAS (visual analog scale): 12.5%, female: 6.1%, joint
surgery: 5.9%, non-orthopedic surgery: 5.4%, duration of
disease: 1.8% and occurrence of fractures: 1.3%. CONCLU-
SIONS: QOL of RA patients is deeply inﬂuenced by the disability
together with comorbidity. Management for the control of both
disease activity and comorbidity is crucial.
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OBJECTIVES: The French public health law of 9 August 2004
took this need into consideration and provided for the imple-
mentation of a quality of life improvement programme for those
affected by chronic illnesses. Furthermore, the 87th of the 110
Public Health objectives is aimed at “Improving the quality of
life of those suffering from osteoarthritis” Describe what impact
treating sufferers of osteoarthritis has on their quality of life.
METHODS: Quality of life was also evaluated for subjects suf-
fering from gonarthritis using the SF-12 score, which is an
approved generic tool for determining the physical and mental
state of health of populations. RESULTS: A total of 256 subjects
suffering from gonarthritis were randomised into 2 groups: 127
randomised subjects were placed in the group treated with ACS
Avian, and 129 randomised subjects in the group receiving the
placebo. Upon inclusion, the PCS-12 scores were 36.43 and
36.64 for the group treated with ACS Avian and the group
receiving the placebo respectively. The 2 groups were similar
upon inclusion. After 6 months of treatment, the PCS-12 scores
were 42.25 and 39.47 for the group treated with ACS Avian and
the group receiving the placebo respectively. There was a statis-
tically signiﬁcant improvement in the physical dimension score
of the group of patients treated with ACS Avian compared with
that of the placebo group (p < 0.05). CONCLUSIONS: These
various studies conﬁrm the sharp deterioration in the physical
dimension of quality of life of patients with gonarthritis. There
was a statistically signiﬁcant improvement in the physical dimen-
sion score of the group of patients treated with ACS Avian
compared with that of the placebo group. This data conﬁrms the
pertinence of both the public health objective ﬁxed by the health
authorities, and the use of ACA Avian in the treatment of
osteoarthritis.
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OBJECTIVES: Over the last few years, in addition to traditional
mortality and morbidity indexes, new measuring instruments
for assessing state of health have been developed. One of the
applications of these new instruments is the self-assessment, by
patients, of their state of health. Quality of life is therefore
readily taken into consideration today when assessing state of
health, whether in terms of understanding the consequences of
a pathology, comparing the impact of alternative strategies, or
evaluating the effect of health policies. The 87th of the 110
public health objectives is aimed at “Limiting the disability and
improving the quality of life of those suffering from osteoarthri-
tis” Compare the level of quality of life in sufferers of osteoar-
thritis with that of the population in general and other
pathologies. METHODS: In order to evaluate the quality of life
of osteoarthritis patients, SF-12 scores were calculated for 301
patients suffering from femorotibial gonarthritis and 1,945 rep-
resentative subjects of the French population aged 15 and over.
The SF-12 score is a generic tool used to assess the physical and
mental state of health of populations. The higher the score, the
better the quality of life. RESULTS: The average PCS-12 score
was considerably lower in osteoarthritis patients (36.08  7.88)
compared with that of the population in general (49.87  8.32).
MCS-12 scores were similar for both populations (48.88 
10.24 and 46.77  9.69 respectively). There was a strong cor-
relation between PCS-12 scores and those of the Lequesne algo-
functional index (p < 0.0001), knee pain at rest (p = 0.0013) and
in activity (p < 0.0001). There was a strong correlation between
MCS-12 scores and those of the Lequesne index (p < 0.003), and
at the limitation of the walking perimeter in particular. For
comparison purposes, PCS-12 and MCS-12 scores for an Ameri-
can population were 46.47 and 52.99 respectively for hyperten-
sion, 40.02 and 51.15 for a cardiac accident, and 44.84 and
52.49 for type II diabetes. Little SF-12 data exists in France. A
study carried out in 2002 on the benign hypertrophy of the
prostate (BHP) gave PCS-12 and MCS-12 scores of 46 and 47.2
respectively. CONCLUSIONS: These studies conﬁrm the sharp
deterioration in the quality of life of patients with gonarthritis,
both compared with the population in general and compared
with patients affected by other chronic pathologies. Deteriora-
tion of the physical dimension was observed, associated with
pain and functional disability. The mental dimension of quality
of life seemed less affected, and was associated with the limita-
tion of the walking perimeter. This data conﬁrms the pertinence
of the 87th public health objective.
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OBJECTIVES: Characterized Chondrocytes Implantation (CCI),
a knee cartilage repair technique using an autologous cell therapy
product (ChondroCelect®), results in better structural repair
than microfracture as demonstrated in a prospective randomized
clinical trial (Saris, Vanlauwe et al. 2008). The SF-36 question-
naire collected along the trial allowed the calculation of utility
scores. This analysis aims to quantify the gap in utility levels by
surgery outcome. METHODS: Patients were split by response
status to the self-reported Knee injury and Osteoarthritis
Outcome Score (KOOS) and pain Visual Analog Scale (VAS)
regardless of the treatment received. Utility scores were derived
from the SF-36 via a validated algorithm and compared between
responders (overall KOOS increase >=10%, VAS decrease
>=20% vs. baseline) and non-responders at Months 24, 30 and
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